I guess the point I'm making is increasing the vasculature as we age is something well on top of just pioneering synaptic health. It's something that's easy to understand why it would work and something different that Alkon can now speak about in these conferences. The latest research is moving bryostatin up to the preventative stages and that's something I've never heard Perry speak upon. SAB members speak and do research for multiple companies all the time and he's infrequently commented on our research other than trial data.
Market Data 
Markets 
AI
